Accent Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
31
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$75M
- Investors
-
14
Accent Therapeutics General Information
Description
Developer of cancer therapeutics designed to provide treatment using RNA structure, stability, function, and translation in cell biology. The company's cancer therapies target RNA-modifying proteins that provide cells with a mechanism for regulating proteins critical for cellular growth and differentiation, enabling patients to get small-molecule therapies for cancer treatments.
Contact Information
Website
www.accenttx.comCorporate Office
- 1050 Waltham Street
- Suite 201
- Lexington, MA 02421
- United States
Corporate Office
- 1050 Waltham Street
- Suite 201
- Lexington, MA 02421
- United States
Accent Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series C) | 20-Dec-2023 | $75M | Completed | Clinical Trials - Phase 1 | ||
| 2. Early Stage VC (Series B) | 23-Apr-2020 | Completed | Pre-Clinical Trials | |||
| 1. Early Stage VC (Series A) | 18-May-2018 | $40M | $40M | Completed | Pre-Clinical Trials |
Accent Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 40,250,000 | $0.000010 | $0.06 | $1 | $1 | 1x | $1 | 19.09% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Accent Therapeutics Comparisons
Industry
Financing
Details
Accent Therapeutics Competitors (47)
One of Accent Therapeutics’s 47 competitors is MaveriX Oncology, a Venture Capital-Backed company based in Palo Alto, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MaveriX Oncology | Venture Capital-Backed | Palo Alto, CA | ||||
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Senti Biosciences Holdings | Formerly VC-backed | South San Francisco, CA | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Arvinas | Formerly VC-backed | New Haven, CT |
Accent Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Accent Therapeutics Patents
Accent Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025255238-A1 | Inhibitors of kif18a and uses thereof | Pending | 05-Jun-2024 | ||
| WO-2025080900-A1 | Inhibitors of the rna helicase dhx9 for use in the treatment of dna damage repair deficient, homologous recombination deficient, and cancers having a brca loss of function mutation | Inactive | 10-Oct-2023 | ||
| WO-2025038462-A2 | Inhibitors of rna helicase dhx9 and uses thereof | Inactive | 11-Aug-2023 | ||
| WO-2025038462-A3 | Inhibitors of rna helicase dhx9 and uses thereof | Inactive | 11-Aug-2023 | ||
| US-20260297679-A1 | Assays for monitoring inhibition of rna helicase dhx9 | Pending | 15-Apr-2023 | C12Q1/6886 |
Accent Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Accent Therapeutics Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bristol-Myers Squibb | Corporation | Minority | ||
| Johnson & Johnson JJDC | Corporate Venture Capital | Minority | ||
| Mirae Asset Capital | Venture Capital | Minority | ||
| Mirae Asset Capital Life Science | Venture Capital | Minority | ||
| Mirae Asset Global Investments (Asset Management) | Asset Manager | Minority |
Accent Therapeutics FAQs
-
When was Accent Therapeutics founded?
Accent Therapeutics was founded in 2017.
-
Where is Accent Therapeutics headquartered?
Accent Therapeutics is headquartered in Lexington, MA.
-
What is the size of Accent Therapeutics?
Accent Therapeutics has 31 total employees.
-
What industry is Accent Therapeutics in?
Accent Therapeutics’s primary industry is Drug Discovery.
-
Is Accent Therapeutics a private or public company?
Accent Therapeutics is a Private company.
-
What is the current valuation of Accent Therapeutics?
The current valuation of Accent Therapeutics is .
-
What is Accent Therapeutics’s current revenue?
The current revenue for Accent Therapeutics is .
-
How much funding has Accent Therapeutics raised over time?
Accent Therapeutics has raised $178M.
-
Who are Accent Therapeutics’s investors?
Bristol-Myers Squibb, Johnson & Johnson JJDC, Mirae Asset Capital, Mirae Asset Capital Life Science, and Mirae Asset Global Investments (Asset Management) are 5 of 14 investors who have invested in Accent Therapeutics.
-
Who are Accent Therapeutics’s competitors?
MaveriX Oncology, Marengo Therapeutics, Senti Biosciences Holdings, Centrose, and Arvinas are some of the 47 competitors of Accent Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
